What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the first 44 amino acids of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus. This modification stabilises the peptide against dipeptidyl peptidase-4 (DPP-4) degradation, extending its half-life from minutes to approximately 30–40 minutes — sufficient to produce a sustained pulse of growth hormone release.

Unlike exogenous growth hormone administration, tesamorelin stimulates the body's own somatotroph cells in the anterior pituitary to release growth hormone in a physiological, pulsatile pattern. This preserves the natural feedback mechanisms — including growth hormone's negative feedback on its own secretion — which direct GH administration bypasses entirely.

Mechanism of Action

How Tesamorelin Works

Tesamorelin binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary gland. This binding activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP), which stimulates the synthesis and release of growth hormone. The released GH then acts on the liver and peripheral tissues to produce insulin-like growth factor 1 (IGF-1), the primary mediator of GH's anabolic and lipolytic effects.

The critical distinction from direct GH administration is physiological regulation. Because tesamorelin works through the pituitary, the released growth hormone is subject to natural feedback control: somatostatin from the hypothalamus inhibits further GH release when levels rise, and IGF-1 exerts negative feedback on both the hypothalamus and pituitary. This regulatory architecture reduces the risk of supraphysiological GH levels that can occur with exogenous GH administration.

At the tissue level, growth hormone stimulates lipolysis — the breakdown of stored triglycerides in adipocytes into free fatty acids and glycerol. GH also promotes hepatic gluconeogenesis, protein synthesis in muscle, and the production of IGF-1, which mediates many of GH's growth-promoting and metabolic effects. The net result in research models is a shift in body composition: reduction in fat mass — particularly visceral fat — with preservation or modest increase in lean body mass.

Visceral Fat Research

Clinical Evidence

Tesamorelin is distinguished from other growth hormone secretagogues by the depth of its clinical trial data. Multiple randomised, placebo-controlled trials have demonstrated that tesamorelin administration produces statistically significant reductions in visceral adipose tissue (VAT) — the metabolically active fat depot stored around internal organs — as measured by CT scan.

Visceral fat is a recognised marker in metabolic research. Unlike subcutaneous fat, visceral adipose tissue is directly implicated in insulin resistance, dyslipidaemia, and inflammatory signalling. The preferential reduction of visceral fat over subcutaneous fat observed with tesamorelin suggests a targeted mechanism: visceral adipocytes express higher densities of growth hormone receptors, making them more responsive to GH-mediated lipolysis.

Clinical studies have also examined tesamorelin's effects on lipid profiles, liver fat content, and inflammatory markers. The compound's ability to reduce hepatic steatosis (fatty liver) in research subjects has generated particular interest given the growing prevalence of non-alcoholic fatty liver disease in metabolic research populations.

Research Context

Growth Hormone Decline and Body Composition

Growth hormone secretion declines approximately 14% per decade after age 30 — a process termed somatopause. This age-related decline is associated with changes in body composition: increasing visceral fat, decreasing lean muscle mass, reduced bone mineral density, and altered lipid metabolism. Tesamorelin's mechanism — restoring physiological GH release rather than replacing it — positions it as a tool for investigating whether these age-related changes can be modulated through the endogenous GH axis.

Research has also explored the relationship between growth hormone, sleep architecture, and circadian rhythm. GH release is naturally pulsatile, with the largest pulse occurring during slow-wave sleep. Understanding how tesamorelin interacts with this circadian pattern — and whether timing of administration influences its effects on body composition and fat metabolism — is an active area of investigation.

All products are research compounds intended for laboratory research use only. Not for human or veterinary use. Kinetic Labs does not provide dosing guidance, therapeutic recommendations, or medical advice of any kind.